Quantcast

Latest Splenomegaly Stories

2012-03-01 11:13:57

People with a blood cancer – myelofibrosis – can benefit from a drug called ruxolitinib, according to a randomized, double-blind, placebo-controlled clinical trial that included patients and researchers from the Stanford University School of Medicine. The results of the multi-site phase-3 trial, which will be published in the March 1 issue of the New England Journal of Medicine, led the Food and Drug Administration to approve the drug in November as treatment for people with...

2012-03-01 11:12:35

Ruxolitinib shrinks swollen spleens, eases debilitating symptoms of incurable malignancy A drug that relieves the severe symptoms of a life-threatening bone marrow cancer called myelofibrosis also improves the survival of patients with the disease, according to a phase III clinical trial published in the March 1 edition of New England Journal of Medicine. "The Phase I/II clinical trial showed that ruxolitinib improves quality of life for many patients with myelofibrosis and now this...

2011-12-12 17:35:47

In a major advance in treatment, a multicenter study found that ruxolinitib did a better job than off-label chemotherapy drugs reducing the terrible symptoms associated with myelofibrosis, including pain, enlarged spleen, anemia, fever, chills, fatigue, and weight loss. The results were presented today at the annual meeting of the American Society of Hematology and Oncology in San Diego. Myelofibrosis is a bone marrow disorder that disrupts the body's normal production of blood cells,...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'